A Prospective, Multi-center, Open-label, Single-arm, Phase 2 Study to Assess the Efficacy and Safety of Clazosentan in Reversing Angiographically-confirmed Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated by Surgical Clipping or Endovascular Coiling

Trial Profile

A Prospective, Multi-center, Open-label, Single-arm, Phase 2 Study to Assess the Efficacy and Safety of Clazosentan in Reversing Angiographically-confirmed Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated by Surgical Clipping or Endovascular Coiling

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Clazosentan (Primary)
  • Indications Subarachnoid haemorrhage
  • Focus Therapeutic Use
  • Acronyms REVERSE
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 14 Jun 2017 Status changed from recruiting to completed.
    • 26 May 2017 This trial has been prematurely ended in Finland, according to European Clinical Trials Database record.
    • 22 May 2017 Results from this trial are expected to be discussed with health authorities by the end of 2017, according to an Actelion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top